



SHUKRA
PHARMACEUTICALS LTD.

14th September, 2017

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai

Ref.: Your mail dated 12/09/2017 Scrip Code:- 524632

Dear Sir/Madam,

Sub: Submission of Financial Result for the quarter ended on 30th June, 2017

With reference to above, please find Financial Result for the quarter ended on 30th June, 2017 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking you.

Yours faithfully,

For Shukra Pharmaceuticals Limited
(Formerly known as Relish Pharmaceuticals Limited)


Chandresh Patel
Director
DIN: 07032481

Encl.: As above

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317



SHUKRA

PHARMACEUTICALS LTD.

Financial Results by Company

PART I						(Rs. in Lakhs)
Statement of Standalone Unaudited Results for the Quarter Ended 30/06/2017						
	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended
		(30/06/2017)	(31/03/2017)	(30/06/2016)	(30/06/2017)	(31/03/2017)
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operation					
	Other Operating Revenue	100.83	204.18	93.60	100.83	517.23
II	Other income	2.01	(1.04)	0.20	2.01	2.68
III	Total Revenue (I + II)	102.84	203.14	93.80	102.84	519.91
IV	Expenses					
	(a) Cost of materials consumed	25.28	12.39	24.81	37.67	86.07
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	© Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	15.21	4.91	15.21	12.03
	(d) Employee benefits expense	25.47	33.61	24.30	25.47	118.21
	(e) Finance Cost	0.19	0.00	0.00	0.19	0.00
	(f) Depreciation and amortisation expense	12.50	12.99	11.20	12.50	46.59
	(g) Other expenses	29.17	73.71	8.79	29.17	152.09
	Total expenses	92.61	147.91	74.01	120.21	414.99
V	Profit / (Loss)before exceptional and extraordinary items and tax (III - IV)	10.23	55.23	19.79	(17.37)	104.59
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	10.23	55.23	19.79	(17.37)	104.59
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	Profit before tax (VII- VIII)	10.23	55.23	19.79	(17.37)	104.59
X	Tax expense - Provision for taxation	3.07	22.71	6.00	0.00	38.71
XI	Net Profit / (Loss) or the period from continuing operations (VII-VIII)	7.16	32.52	13.79	(17.37)	65.88
XII	Profit/(loss) from discontinuing operations	7.16	32.52	13.79	(17.37)	65.88
XIII	Tax expense of discontinuing operations	7.16	32.52	13.79	(17.37)	65.88
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	7.16	32.52	13.79	(17.37)	65.88



CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.
 Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317



SHUKRA

PHARMACEUTICALS LTD.

XV	Profit (Loss) for the period (XI + XIV)	7.16	32.52	13.79	(17.37)	65.88
XVI	Earnings per equity share:	156.57	156.57	156.57	156.57	156.57
	(1) Basic	0.05	0.21	0.09	(0.11)	0.42
	(2) Diluted	0.05	0.21	0.09	(0.11)	0.42

Notes:

1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th August, 2017
2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standar
3. During the quarter ended 30th June 2017, Nil complaints was received and attended.
4. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
5. These financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act, 2013 ('Act') (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
6. Reconciliation of Statement of Profit and Loss reported for previous year under IGAAP to Ind AS Quarter Ended June 30, 2016

Particulars	Item Impacting	As Per IGAAP	Effect on Transition to Ind AS	As Per Ind AS
Revenue from Operations		93.6	NIL	93.6
Other Comprehensive Income		0.2	NIL	0.2
Tax Expenses		6	NIL	6
Profit After Tax		13.79	NIL	13.79

Place : Ahmedabad

Date : 15/09/2017

For Shukra Pharmaceuticals Limited

Chandresh Patel
Director

DIN: 07032481

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317